Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,645 across all filing types
Latest filing 2025-09-20 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
General Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges under Regulation 30 of SEBI Listing Regulations, informing about an ESG rating assigned by an external agency (CRISIL). It states the rating and clarifies that the company did not engage the rating agency. The document is short (2236 characters) and serves as an announcement of an ESG rating update, not a detailed ESG report or annual report. It does not contain financial statements or detailed analysis. This fits best under Environmental & Social Information (SR) as it relates to ESG rating information, but since it is a brief announcement rather than a full ESG report, and given the regulatory context, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a compliance disclosure under SEBI regulations about ESG rating information. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2025-09-20 English
Please find attached the file
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement addressed to stock exchanges regarding the receipt of an ESG rating from CRISIL. It states the rating assigned and clarifies that the company did not engage CRISIL for the rating. The document is dated and signed by the company secretary. There are no financial statements, detailed analysis, or report attachments. The length is only 2236 characters, which is short and typical for a regulatory announcement. It does not contain an actual ESG report or detailed environmental/social information, but rather an announcement of the rating received. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement under SEBI Listing Regulations.
2025-09-20 English
Please find attached the file
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges (NSE and BSE) regarding the execution of a joint venture agreement by a subsidiary of the company. It references compliance with SEBI Listing Regulations and SEBI circulars, indicating it is a regulatory disclosure. The content details the joint venture agreement, shareholding, and business purpose but does not contain financial statements or detailed financial analysis. The document length is 7,876 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. There is no indication that this is a full annual or interim report, audit report, earnings release, or other detailed financial document. It is an announcement of a corporate event (joint venture agreement) pursuant to regulatory requirements. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-09-08 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges (NSE and BSE) regarding the execution of a joint venture agreement by a subsidiary of the company. It references compliance with SEBI Listing Regulations and SEBI circulars, indicating it is a regulatory disclosure. The content details the joint venture agreement, shareholding, and business purpose but does not contain financial statements or detailed financial analysis. The document length is 7,876 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. There is no indication that this is a full annual or interim report, audit report, earnings release, or other detailed financial document. The nature of the disclosure fits the category of a regulatory announcement under SEBI regulations about a material event (joint venture agreement). Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-09-08 English
Acquisition
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges (NSE and BSE) regarding the execution of a joint venture agreement by a subsidiary of the company. It references compliance with SEBI Listing Regulations and SEBI circulars, indicating it is a regulatory disclosure. The content details the joint venture agreement, shareholding, and business purpose but does not contain financial statements or detailed financial performance data. It is an announcement of a corporate action (joint venture agreement) rather than a financial report or earnings release. The document length is 7487 characters, which is sufficient for a detailed announcement but does not constitute a full report like an Annual Report or Interim Report. Therefore, the document fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-09-08 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges (NSE and BSE) regarding the execution of a joint venture agreement by a subsidiary of the company. It references compliance with SEBI Listing Regulations and SEBI circulars, indicating it is a regulatory disclosure. The content details the joint venture agreement, shareholding, and business purpose but does not contain financial statements or detailed financial performance data. It is an announcement of a corporate event (joint venture agreement) rather than a financial report or earnings release. The document length is about 7,487 characters, which is relatively short and focused on disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and disclosures that do not fit other specific categories.
2025-09-08 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.